| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4216511 | Revue des Maladies Respiratoires Actualités | 2011 | 9 Pages |
Abstract
Major advances have been made in recent years in the treatment of pulmonary hypertension with a wide range of available therapeutic option, including prostacyclins, endothelin receptor antagonists, and phosphodiesterase type-5 inhibitors. Results of clinical trials with these compounds have shown that improvements in haemodynamic parameters, exercise capacity as well as WHO functional class might be obtained.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Pulmonary and Respiratory Medicine
Authors
S. Duong-Quy,